[an error occurred while processing this directive] | [an error occurred while processing this directive]
Analysis of clinical value of high-risk factors combined with stratification analysis in predicting clinical prognosis of N2-3M0 nasopharyngeal carcinoma patients
Chen Junni1, Yuan Bo2, Yang Shiping1, Chen Jiawei1, Lin Xiangying1, Li Zhaojun1, Chen Feng3, Wang Zhenping3, Wang Fen1, Wang Yiming1
1Department of Radiation Oncology,Hainan General Hospital,Haikou 570311,China; 2Department of Stomach Intestine Surgery,Hainan General Hospital,Haikou 570311,China; 3Department of Radiology,Hainan General Hospital,Haikou 570311,China
AbstractObjective To evaluate the clinical value of high-risk factors in combination with stratification method in predicting the clinical prognosis of patients diagnosed with N2-3M0 nasopharyngeal carcinoma (NPC). Methods A total of 226 N2-3M0 NPC patients who underwent IMRT from November 2013 to May 2015 were enrolled in this study. The relationship between tumor volume, cervical metastatic lymph node characteristics (necrosis and fusion) and T and N staging was analyzed. The high-risk factors that affected the survival were identified. The value of high-risk factors combined with stratification method in predicting the clinical prognosis was assessed. Results N3 staging, Vn≥47.15cm3 and lymph node fusion (LNF) were the high-risk factors for distant metastasis in patients with stage N2-3M0 NPC. All patients were classified into the low-risk, medium-risk, high-risk and extremely high-risk groups according to high-risk factors. For patients in the low-risk, medium-risk, high-risk and extremely high-risk groups, the 3-year overall survival rates were 84.2%,76.7%,58.7% and 36.4%(all P<0.001), 87.3%,85.2%,54.5% and 12.1% for the distant metastasis-free survival (DMFS) rates (all P<0.001), 76.8%,74.3%,49.2% and 12.1%for the progression-free survival (PFS) rates (all P<0.001), and 89.2%,88.5%,91.5% and 88.3% for the loco-regional recurrence-free survival (LRRFS) rates (P=0.914), respectively. The risk stratification method showed the best curve separation for DMFS compared to the Vn, N staging and LNF classification groups (all P<0.05). Conclusion High-risk factors in combination with stratification method has the highest clinical value in predicting the clinical prognosis of N2-3M0 NPC patients.
Fund:Hainan Natural Science Foundation Project (817304)
Cite this article:
Chen Junni,Yuan Bo,Yang Shiping et al. Analysis of clinical value of high-risk factors combined with stratification analysis in predicting clinical prognosis of N2-3M0 nasopharyngeal carcinoma patients[J]. Chinese Journal of Radiation Oncology, 2019, 28(12): 885-889.
Chen Junni,Yuan Bo,Yang Shiping et al. Analysis of clinical value of high-risk factors combined with stratification analysis in predicting clinical prognosis of N2-3M0 nasopharyngeal carcinoma patients[J]. Chinese Journal of Radiation Oncology, 2019, 28(12): 885-889.
[1]Zhang MX,Li J,Shen GP,et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy:a 10-year experience with a large cohort and long follow-up[J]. Eur J Cancer,2015,51(17):2587-2595. DOI:10.1016/j.ejca.2015.08.006. [2]Ng WT,Lee MC,Hung WM,et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys,2011,79(2):420-428. DOI:10.1016/j.ijrobp.2009.11.024. [3]孙学明,黄莹,陈春燕,等.N晚期鼻咽癌调强放疗远期疗效评价[J]. 中华放射肿瘤学杂志,2013,22(3):225-229. DOI:10.3760/cma.j.issn.1004-4221.2013.03.014. Sun XM,Huang Y,Chen CY,et al. Evaluation of the long-term efficacy of advanced nasopharyngeal cancer in N[J]. Cin J Radait Oncol,2013,22(3):225-229.DOI:DOI:10.3760/cma.j.issn.1004-4221.2013.03.014. [4]Amin MB,Edge S,Greene F,et al. AJCC cancer staging manual[M].8th ed. New York:Springer,2017. [5]Sun Y,Li WF,Chen NY,et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:a phase 3,multicentre,randomised controlled trial[J]. Lancet Oncol,2016,17(11):1509-1520. DOI:10.1016/S1470-2045(16)30410-7. [6]Peng H,Chen L,Zhang J,et al. Induction chemotherapy improved long-term outcomes of patients with locoregionally advanced nasopharyngeal carcinoma:a propensity matched analysis of 5-year survival outcomes in the era of intensity-modulated radiotherapy[J]. J Cancer,2017,8(3):371-377. DOI:10.7150/jca.16732. [7]魏嘉旺,黄蓉,余昕,等.3~4周期NACT对N2-N3期鼻咽癌临床价值分析[J]. 中华放射肿瘤学杂志,2017,26(4):380-383. DOI:10.3760/cma.j.issn.1004-4221.2017.04.003. Wei JW,Huang R,Yu X,et al. 3-4 cycle NACT analysis N2-N3 nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2017,26(4):380-383. DOI:10.3760/cma.j.issn.1004-4221.2017.04.003. [8]侯雪,张力,赵充,等. 血浆EB病毒DNA浓度预测鼻咽癌远处转移的研究[J]. 癌症,2006,25(7):785-792. DOI:10.3969/j.issn.1000-467X.2006.07.001. Hou X,Zhang L,Zhao C,et al. Study on the prediction of distant metastasis of nasopharyngeal cancer in plasma EB virus DNA concentration[J]. Chin J Cancer, 2006,25(7):785-792. DOI:10.3969/j.issn.1000-467X.2006.07.001. [9]Peng L,Yang Y,Guo R,et al. Relationship between pretreatment concentration of plasma Epstein-Barr virus DNA and tumor burden in nasopharyngeal carcinoma:an updated interpretation[J]. Cancer Med,2018,7(12):5988-5998. DOI:10.1002/cam4.1858. [10]Fung SY,Lam JW,Chan KC. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma[J]. Chin Oncol,2016,5(2):18. DOI:10.21037/cco.2016.03.07. [11]Chen QY,Guo SY,Tang LQ,et al. Combination of tumor volume and Epstein-Barr virus DNA improved prognostic stratification of stage Ⅱ nasopharyngeal carcinoma in the IMRT Era:a large-scale cohort study[J]. Cancer Res Treat,2017,50(3):861-871. DOI:10.4143/crt.2017.237. [12]Lu L,Li J,Zhao C,et al. Prognostic efficacy of combining tumor volume with Epstein-Barr virus DNA in patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma[J]. Oral Oncol,2016,60(1):18-24. DOI:10.1016/j.oraloncology.2016.06.013. [13]Zhou X,Ou X,Yang Y,et al. Quantitative metastatic lymph node regions on magnetic resonance imaging are superior to AJCC N classification for the prognosis of nasopharyngeal carcinoma[J]. J Oncol,2018,2018:9172585. DOI:10.1155/2018/9172585. [14]Lan M,Huang Y,Chen CY,et al. Prognostic value of cervical nodal necrosis in positive cervical nodal metastasis at MRI maging[J]. Radiology,2015,276(2):619. DOI:10.1148/radiol.15154020. [15]Feng Y,Cao C,Hu Q,et al. Prognostic value and staging classification of lymph nodal necrosis in nasopharyngeal carcinoma after intensity modulated radiotherapy[J].2019,51(3):1222-1230. DOI:10.4143/crt.2018.595. [16]Zhang LL,Li JX,Zhou GQ,et al. Influence of cervical node necrosis of different grades on the prognosis of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy[J]. J Cancer,2017,8(6):959-966. DOI:10.7150/jca.17998. [17]Zhang LL,Zhou GQ,Li YY,et al. Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy:a large-scale retrospective study[J]. Cancer Med,2017,6(12):2822-2831. DOI:10.1002/cam4.1233. [18]Zhou X,Yang YQ,Ou XM,et al. Interplay of tumor spread,volume and Epstein-barr virus DNA in nasopharyngeal carcinoma:feasibility of an integrative risk stratification scheme[J]. J Cancer,2018,9(22):4271-4278. DOI:10.7150/jca.26777.
2019, Vol. 28 
